{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:01:04Z","timestamp":1780444864954,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NCT02327624"],"award-info":[{"award-number":["NCT02327624"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vph.2023.107145","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T02:25:35Z","timestamp":1674872735000},"page":"107145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes"],"prefix":"10.1016","volume":"149","author":[{"given":"William A.E.","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Rollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph. Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel C.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Judge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2023.107145_bb0005","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/heartjnl-2020-316914","article-title":"Antithrombotic therapy for patients with chronic coronary syndromes","volume":"107","author":"Parker","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.vph.2023.107145_bb0010","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/heartjnl-2015-307858","article-title":"Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54","volume":"102","author":"Parker","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.vph.2023.107145_bb0015","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.vph.2023.107145_bb0020","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2023.107145_bb0025","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2023.107145_bb0030","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1161\/CIRCULATIONAHA.120.053294","article-title":"Applying decision analysis to inform the US Food and Drug Administration\u2019s benefit\u2013risk assessment of ticagrelor for primary prevention of myocardial infarction or stroke based on THEMIS","volume":"144","author":"Lackey","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2023.107145_bb0035","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","article-title":"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial","volume":"394","author":"Bhatt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2023.107145_bb0040","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","article-title":"Platelet inhibition with Ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial","volume":"67","author":"Storey","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2023.107145_bb0045","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCULATIONAHA.118.034790","article-title":"Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease (STEEL-PCI)","volume":"138","author":"Orme","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2023.107145_bb0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.31083\/j.rcm2202044","article-title":"Ticagrelor: clinical development and future potential","volume":"22","author":"Sanderson","year":"2021","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.vph.2023.107145_bb0055","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/ijms17030388","article-title":"A comparative study of molecular structure, pKa, lipophilicity, solubility, absorption and polar surface area of some antiplatelet drugs","volume":"17","author":"Remko","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.vph.2023.107145_bb0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11630960-000000000-00000","article-title":"Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor","volume":"51","author":"Teng","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.vph.2023.107145_bb0065","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1365-2141.2000.02208.x","article-title":"The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity","volume":"110","author":"Storey","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.vph.2023.107145_bb0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00003088-199325020-00003","article-title":"Clinical pharmacokinetics of drugs in obesity. An update","volume":"25","author":"Cheymol","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.vph.2023.107145_bb0075","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/eurheartj\/ehy066","article-title":"Antithrombotic therapy and body mass: an expert position paper of the ESC working group on thrombosis","volume":"39","author":"Rocca","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2023.107145_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.615","article-title":"Association between low body weight and cytochrome P-450 enzyme activity in patients with anorexia nervosa","volume":"8","author":"Sandvik","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.vph.2023.107145_bb0085","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/0394632016643550","article-title":"Obesity and kidney disease: beyond the hyperfiltration","volume":"29","author":"Mascali","year":"2016","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.vph.2023.107145_bb0090","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.vph.2023.107145_bb0095","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ahj.2013.12.020","article-title":"Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial","volume":"167","author":"Bonaca","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.vph.2023.107145_bb0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(18)31307-2","article-title":"Weight-adjusted aspirin for cardiovascular prevention","volume":"392","author":"Theken","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2023.107145_bb0105","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.thromres.2014.05.019","article-title":"The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study","volume":"134","author":"Jakubowski","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2023.107145_bb0110","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00392-021-01976-y","article-title":"Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes","volume":"111","author":"Ndrepepa","year":"2022","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.vph.2023.107145_bb0115","first-page":"169","article-title":"Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?","volume":"16","author":"Angiolillo","year":"2004","journal-title":"J. Invasive Cardiol."},{"key":"10.1016\/j.vph.2023.107145_bb0120","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00392-020-01604-1","volume":"109","author":"Ono","year":"2020","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.vph.2023.107145_bb0125","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","article-title":"Platelet inhibition with Ticagrelor 60 mg compared with 90 mg twice-daily in the PEGASUS-TIMI 54 study","volume":"67","author":"Storey","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2023.107145_bb0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-0036-1597298","article-title":"Monitoring antiplatelet therapy","volume":"43","author":"Orme","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.vph.2023.107145_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ehjcvp\/pvw026","article-title":"Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients","volume":"3","author":"Vries","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.vph.2023.107145_bb0140","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/jth.12376","article-title":"Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness","volume":"11","author":"Kakouros","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2023.107145_bb0145","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.ijcard.2014.07.228","article-title":"Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel","volume":"176","author":"Deharo","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2023.107145_bb0150","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.xphs.2020.10.027","article-title":"Correlation of body weight and composition with hepatic activities of cytochrome P450 enzymes","volume":"110","author":"Krogstad","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.vph.2023.107145_bb0155","doi-asserted-by":"crossref","first-page":"20405","DOI":"10.1038\/s41598-019-57002-9","article-title":"Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity","volume":"9","author":"Rodr\u00edguez-Morat\u00f3","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vph.2023.107145_bb0160","doi-asserted-by":"crossref","first-page":"416","DOI":"10.5414\/CP202748","article-title":"Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction","volume":"55","author":"R\u00f6shammar","year":"2017","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2023.107145_bb0165","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.839","article-title":"Exposure-response analyses supporting Ticagrelor dosing recommendation in patients with prior myocardial infarction","volume":"57","author":"R\u00f6shammar","year":"2017","journal-title":"J. Clin. Pharmacol."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189123000058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189123000058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:21:30Z","timestamp":1761528090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189123000058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":33,"alternative-id":["S1537189123000058"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2023.107145","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2023.107145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107145"}}